Testosterone + Alendronate + Placebo Alendronate + Placebo Testosterone

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypogonadism

Conditions

Hypogonadism, Osteopenia, Osteoporosis

Trial Timeline

Oct 1, 2011 → Dec 1, 2014

About Testosterone + Alendronate + Placebo Alendronate + Placebo Testosterone

Testosterone + Alendronate + Placebo Alendronate + Placebo Testosterone is a phase 2 stage product being developed by Merck for Hypogonadism. The current trial status is terminated. This product is registered under clinical trial identifier NCT01460654. Target conditions include Hypogonadism, Osteopenia, Osteoporosis.

What happened to similar drugs?

6 of 19 similar drugs in Hypogonadism were approved

Approved (6) Terminated (3) Active (12)
Topical Testosterone SolutionEli LillyApproved
AndroGel® + PlaceboAbbVieApproved
AndroGel 1.62%AbbVieApproved
NEBIDO + PLACEBOBayerApproved
JatenzoICON plc.Approved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01460654Phase 2Terminated